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Over the past decade, antibody-mediated or humoral rejection in combination with
development of de novo donor-specific antibodies (DSA) has been recognized as a
distinct and common cause of transplant dysfunction and is responsible for one-
third of the failed allografts. Detailed knowledge of the mechanisms that initiate
and maintain B-cell driven antidonor reactivity is required to prevent and better
treat this antidonor response in organ transplant patients. Over the past few years, it
became evident that this response largely depends on the actions of both T follicu-
lar helper (Tfh) cells and the controlling counterparts, the T follicular regulatory
(Tfr) cells. In this overview paper, we review the latest insights on the functions of
circulating (c)Tfh cells, their subsets Tfh1, Tfh2 and Tfh17 cells, IL-21 and Tfr
cells in antibody mediated rejection (ABMR). This may offer new insights in the
process to reduce de novo DSA secretion resulting in a decline in the incidence of
ABMR. In addition, monitoring these cell populations could be helpful for the
development of biomarkers identifying patients at risk for ABMR and provide
novel therapeutic drug targets to treat ABMR.
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1 | INTRODUCTION
Antibody mediated rejection (ABMR) or “humoral” rejec-
tion is considered a major cause of early and late allograft
failure.1-3 Interaction between T and B cells is critical for the
humoral immune response. This can be protective in case of
vaccination or injurious during allograft rejection after organ
transplantation.
A major function of alloantigen-activated CD4+ T helper
cells is providing help to antigen-activated B cells that pro-
duce antibodies. T helper cells are important in controlling
of immunoglobulin class switching, somatic hypermutation
of immunoglobulin variable region genes and secretion of
high affinity antibodies.4 These events occur mainly in ger-
minal centers (GC) in secondary lymphoid tissues. The
CD4+ T helper cells entering the GC are recognized as T fol-
licular helper (Tfh) cells since the year 2000.5,6 The loss of
CCR7 together with the expression of the chemokine recep-
tor CXCR5 allows the Tfh cells to relocate from the T-cell
zones to the B-cell follicle and cognate CXCL13 (the ligand
for CXCR5) in germinal centers.7 Furthermore, Tfh cells
express high levels of the costimulatory molecule CD40L,
inducible co-stimulator ICOS, the transcription factor Bcl6,
the immune checkpoint PD-1 (CD279), the lymphocyte acti-
vation and differentiation molecules CD84, CD200, SAP
and cMAF and the main cytokine IL-21.5,6,8-10 These factors
play an important role in the activation, differentiation and
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survival of B cells. B cells that differentiate into plasma cells
can secrete donor-specific HLA antibodies (DSA) and may
already exist prior to transplantation11 or develop de novo
after transplantation.12 DSA are associated with acute and
chronic allograft dysfunction resulting in progression of
graft deterioration.11-13 Once DSA are developed, therapeu-
tic option to clear these DSA is challenging.14 Therefore,
alternative biomarkers to predict ABMR with DSA are nec-
essary and could be a therapeutic target to prevent early
transplant survival.
In this review we will focus on circulating Tfh cells,
functional subsets of Tfh cells and the role of Tfr cells.
Thereafter, we will summarize and discuss the role of circu-
lating Tfh and Tfr cells in human organ transplantation and
discuss how these cells might contribute to humoral rejec-
tion after transplantation.
2 | CIRCULATING TFH CELLS IN
PERIPHERAL BLOOD
The presence of CD4+CXCR5+ Th cells is not limited in sec-
ondary lymphoid tissues, as blood contains also this special
type of cell population. Initially, these blood cells were
described as recently activated T cells.15 Later, studies
showed that blood CD4+CXCR5+ T cells have a superior
capacity to CXCR5− cells in inducing B cells to plasmablasts
that secrete immunoglobulins.16-18 These reports show that
blood CD4+CXCR5+ T cells contain long-lived memory
cells recognized as a circulating counterpart of Tfh cells. In
addition, CXCR5+ T cells are more potent than CXCR5−
memory CD4 T cells in providing help to B cells for antibody
production.5,6,16,19 These cells are currently called blood
memory Tfh cells or circulating Tfh (cTfh) cells.
IL-12 plays an important role in differentiation of human
Tfh cells, because it maintains the expression of ICOS and
CXCR5 on naïve T cells. IL-12 induces IL-21 expression
trough a STAT3-dependent mechanism and is activated in
human T cells exposed to IL-12. STAT3 binds to the promotor
of IL-21 and Bcl6 genes.20,21 STAT3 seems to have a non-
redundant role in human Tfh cell differentiation. The expres-
sion of phosphorylated STAT3 on cTfh cells (CD4+CXCR5+)
is positively correlated with cTfh cell frequency.22
Both GC Tfh and cTfh express CXCR5, while the expres-
sion of other markers is different. In contrast to GC Tfh, ICOS
is only expressed in <1% of cTfh express in healthy individ-
uals.18,23,24 It is suggested that CD4+CXCR5+CCR7+PD-
1−ICOS− T cells are circulating before they will relocate to
GC. After antigen reexposure these cells will be differentiated
into mature Tfh with loss of CCR7 and increased expression
of PD-1 and ICOS to stimulate antibody responses.23 There-
fore, CD4+CXCR5+CCR7−PD-1+ICOS+ T cells could be
identified as activated cTfh cells. This relocation can also
clarify that the frequency of ICOS+cTfh cells were increased
transiently after vaccination.23,24 CCR7−PD-1+ cTfh cells have
a more prominent helper function than PD-1− cTfh cells, prob-
ably due to the high expression of IL-21 and ICOS. Recently,
La Muraglia et al25 showed that the increase in activated
ICOS+PD-1+ cTfh occurs earlier than the total cTfh
(CD4+CXCR5+) and even precedes the generation of DSA in
a murine transplant model.
Because in literature cTfh were differentially defined
according to their phenotype, below the phenotype will be
quoted in brackets.
3 | FUNCTIONAL SUBTYPES OF
TFH CELLS
Th1, Th2 and Th17 cells all have signature cytokines that are
responsible for their function and express their specific tran-
scriptional regulators, T-bet, GATA3 and RORγt, respec-
tively.26 Chemokine receptors could dissect T-cell subsets
according to their migratory capacity. CXCR3 represents dif-
ferentiated Th1 cells, CCR4 differentiated Th2 cells and
CCR6 differentiated Th17 cells.27 These three subsets can
also be classified within cTfh cells: Tfh1 (CD4+CXCR5+
CXCR3+CCR6−), Tfh2 (CD4+CXCR5+CXCR3−CCR6−)
and Tfh17 (CD4+CXCR5+CXCR3−CCR6+). These cells
produce their specific cytokines IFN-γ (Tfh1), IL-4 (Tfh2)
and IL-17 (Tfh17).16 These subsets have a different capacity
to regulate humoral immunity. Only Tfh2 and Tfh17 cells
induce naïve B cells to produce immunoglobulins via IL-21.
Tfh2 cells promote IgG and IgE secretion and Tfh17 promote
IgG and IgA secretion.16 Bentibibel et al24 showed that Tfh1
cells can induce memory B cells, but not naïve B cells, to dif-
ferentiate into plasma cells.
The biological significance of Tfh subsets is mostly
reported in autoimmunity. The frequency of Tfh2 cells is
increased in patients with active SLE disease, while the Tfh1
decreased, accompanied with high IgG levels in autoanti-
bodies patient's sera. The proportion of Tfh17 cells is not
associated with disease activity.28 While in juvenile derma-
tomyositis, idiopathic inflammatory myopathy, Guillain-
Barré syndrome and rheumatoid arthritis increased numbers
of Tfh2 and Tfh17, and not Tfh1, were found.16,29-31
Mainly, the Tfh2 cells were increased in IgG4-related dis-
ease32 and Tfh17 cells are associated with disease severity in
psoriasis and Hashimoto's thyroiditis.33,34
4 | T FOLLICULAR REGULATORY
CELLS
Conventional FoxP3+ regulatory T cells suppress the activa-
tion and proliferation of effector T cells and are critical to
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prevent autoimmunity and may prevent rejection in solid
organ transplantation.35 Due to the plasticity of helper T
cells, Tregs can turn on Bcl6 and can express the follicular
homing receptor CXCR5, resulting in Tfr phenotype.36,37
Only a subset of Treg, 10% to 15%, can inhibit Tfh cells in
murine and human lymphoid tissue.36,37 Tfr cells share phe-
notypic characteristics of both conventional FoxP3+ Tregs
and Tfh cells by expressing FoxP3, Bcl6, CXCR5, PD-1,
SAP and CD28. Both Tfh and Tfr cells co-localize in germi-
nal centers. Tfr cells control the germinal center reaction by
limiting the numbers of Tfh cells, their cytokine production
and subsequent the humoral response.36-38 Tfr cells are
mainly induced by exposure to self-antigen to prevent auto-
immunity, because defects in Tfr cells lead to spontaneous
GC formation and humoral autoimmunity.39
Remarkably, the T-cell receptor repertoire of Tfr cells
resembles that of Treg and differs from the repertoire of Tfh
cells.40 This suggests, that Tfh cells promote humoral
responses to nonself antigens, while Tfr cells inhibit the for-
ming of autoantibody-mediated autoimmunity and are also
able to regulate nonantigen-specific clones.
In the last decade, it is described that the Tfr/Tfh ratio may
be a marker for the human humoral immune response. The
Tfr/Tfh ratio was inversely correlated with the clinical severity
of myasthenia gravis,41 primary biliary cholangitis42 and rheu-
matoid arthritis,43 and increased ratios were reported in patients
with ankylosing spondylitis,44 Hashimoto's thyroiditis.45
The importance of Tregs for the control of autoimmunity
and their role in transplantation has been described since
two decades. However, data about the role of Tfr cells after
transplantation in literature are scarce.
5 | CIRCULATING TFH AND TFR
CELLS IN ORGAN
TRANSPLANTATION
Tfh cells accumulate more in lymph nodes removed during
kidney transplantation compared with corresponding blood
cTfh taken prior to transplantation.46 The percentage of cTfh
cells (CD4+CCR5+) is strongly correlated with the percent-
age of lymph node Tfh cells.46 Tfh cells in the lymph nodes
expressed significantly more ICOS and PD-1 than their cTfh
counterparts.46 Before and 3 months after kidney transplan-
tation the percentage of cTfh cells (CD4+CXCR5+) is com-
parable, while their IL-21 production was decreased after
transplantation.47 In addition, the percentage of cTfh was
higher in patients with preexistent DSA.47 However, Cano-
Romero et al48 found that the number of cTfh
(CD4+CXCR5+CCR7lowPD-1+) increased after transplanta-
tion. These authors also found that patients with previous
exposure to alloantigens showed a higher Tfh frequency
prior to transplantation than first transplant recipients.
Before and after liver transplantation, the cTfh (CD4+
CXCR5+) and cTfh17 remained stable in time. Nevertheless,
the cTfh1 cells were reduced at 1 week and 1 month after
transplantation compared with before liver transplantation, and
the cTfh2 cells increased at 1 week and decreased to similar
levels as before transplantation at 1 month posttransplant.49
5.1 | Graft rejection and tolerance
Pretransplant cTfh (CD4+CXCR5+CCR7−PD-1+) were
increased in patients with a previous graft or who received
blood transfusions compared with those who did not, and was
higher in patients who developed rejection48 (Table 1). Zhang
et al50 studied the different subsets of cTfh and rejection.
These authors showed that the proportion of Tfh2 was
increased and Tfh17 was decreased in patients with acute
rejection compared with those without rejection. The propor-
tion of Tfh1 cells was comparable. IL-21 is the most impor-
tant cytokine of human Tfh cell differentiation and also
contributes to antibody production.57 The IL-21 serum levels
are higher in patients with rejection after liver transplantation
than without rejection.50 The highest IL-21 mRNA expression
was found in heart transplant recipients undergoing rejection
compared with those free from rejection.51 In renal transplant
biopsies, IL-21 and Bcl6 positive cells were only observed
during rejection.52 In addition, patients who developed DSA
after kidney transplantation had higher pretransplant IL-21
plasma concentrations and more IL-21+ cTfh
(CD4+CD45RO+CXCR5+) than patients who did not
develop DSA.58 We also showed that higher numbers of cir-
culating donor-reactive IL-21 producing cells were found
pretransplant in patients who had anti-HLA antibodies com-
pared with those without antibodies.53 Furthermore, high
numbers of pretransplant donor-reactive IL-21 producing cells
were associated with early rejection episodes. Moreover, high
numbers of donor-reactive IL-21 producing cells at 6 months
after transplantation correlated with late rejections.53
Renal transplant patients with signs of chronic rejection
had a significantly higher percentage of cTfh cells
(CD4+CXCR5+) compared with stable patients, while PD-1
was downregulated in cTfh cells from patients with chronic
rejection. ICOS expression within Tfh cells and serum IL-21
were comparable between these patients.54 Although, Chen
et al55 showed that the percentage of cTfh cells (CD4+
CXCR5+ICOS+) in patients with and without chronic renal
allograft dysfunction (CRAD) were comparable, while the
proportion Tfh17 (CD4+CXCR5+IL-17+CCR3−CCR6+)
and Tfh2 (CD4+CXCR5+IL-4+CCR3−CCR6−) were higher
in patients with CRAD. However, they found comparable
numbers of Tfh cells (CD4+CXCR5+) and lower numbers of
Tfr cell (CD4+CXCR5+FoxP3+) in biopsies from patients
with ABMR compared with those without ABMR.55
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Tolerant patients had a lower percentage cTfh (CD4+
CD45RA−CXCR5+) than stable renal transplant patients
using immunosuppression. Also the activation molecules
PD-1 and ICOS were lower in the tolerant patients.56 The
absolute numbers of cTfh were comparable between the two
groups. In contrast to the stable patients, the cTfh cells of
tolerant patients failed to produce IL-21 and could not
induce B-cell IgG production preventing de novo DSA
production.
5.2 | Immunosuppression after
transplantation
In contrast to basiliximab (anti-CD25 monoclonal antibody)
induction therapy, anti-thymocyte globuline (ATG) induction
depleted cTfh (CD3+CD4+CD45RO+CCR5+) in kidney trans-
plant recipients.58 The absolute number of cTfh was signifi-
cantly lower from 1 month to 1 year posttransplantation in
patients receiving ATG compared with those with basiliximab,
while the percentage remain unchanged. This drop in Tfh cells
was confirmed by Cano-Romero et al.48 Patients treated with
ATG had lower cTfh numbers than patients treated with bas-
iliximab even at 6 months after transplantation. These cTfh
were higher in patients who developed de novo DSA com-
pared with the unsensitized patients. ATG induction therapy
skewed the cTfh cells to the Th1, effector memory phenotype
(CXCR5+CXCR3+CD45RO+CD62L−) and elevated PD-1
expression compared with basiliximab.58 Patients with DSA
had an increased Tfh/Treg ratio (Treg: CD127−FoxP3+) com-
pared with stable patients.58
To allow ABO or HLA incompatible kidney transplanta-
tion often rituximab (anti-CD20 monoclonal antibody) therapy
is given to reduce antibody titers and depletion of circulating
B cells. Rituximab in combination with tacrolimus and myco-
phenate mofetil removes circulating naïve B cells and not
memory cells, and lymph node B cells in GC are also
depleted. However, Tfh and Tfr cells are still present.59 Appar-
ently, these cells do not require the GC for maintenance.
Kidney transplant recipients treated with tacrolimus have
higher numbers of CD4+CCR5+ and CD4+CXCR5+PD-1+
cTfh cells than patients treated with sirolimus, while
CD4+CCR5+ICOS+ cTfh could not discriminate the patient
groups.60 Also phosphorylated STAT3 within cTfh
(CD4+CXCR5+) is higher in the tacrolimus patients than the
sirolimus-treated patients. Both the proportion and absolute
cell number of cTfh (CD4+CXCR5+PD-1+), activated cTfh
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cells (CD4+CXCR5+PD-1++), Tfh1, Tfh2 and Tfh17 cells
were reduced in tacrolimus-treated patients compared with
untreated patients prior to transplantation, while the conven-
tional Th1 cells, Treg and Tfr were comparable.61 When
tacrolimus was added in vitro, the Tfh generation
(CD4+CRCR5+) was only minimally (7%) inhibited and the
CD4+CXCR5+PD-1+ Tfh cells were partially (48%)
decreased.62 Tacrolimus could inhibit 50% of the donor
antigen-driven plasmablast formation.62 In the lymph nodes,
only Tfh cells (CD4+CXCR5+PD-1+) were reduced after
tacrolimus treatment, and PD-1++Tfh cells and Bcl6+Tfh
cells could not discriminate the two groups of patients.
Dahdal et al63 also showed that immunosuppression reduced
the number of Tfh1 and Tfh2, but not Tfh17, cells compared
with healthy individuals.
The costimulatory signal inhibitor belatacept binds CD80
and CD86 on antigen-presenting cells (APC) and could pre-
vent de novo DSA formation and ABMR in a nonhuman
kidney transplant model by inhibition of Tfh cells in lymph
nodes.64 Also in kidney transplant recipients treated with
belatacept de novo DSA were significantly lower than
cyclosporine-treated patients,65 due to reduced proportion of
cTfh cells (CXCR5+CD45RA− and CXCR5+CD45RA−
PD1+ICOS+).66 These authors showed that in vitro addition
of belatacept reduced plasmablast formation and immuno-
globulin production.66 In an earlier study was shown that
belatacept could only partly suppress donor-antigen
driven plasmablast formation and was comparable with
tacrolimus.62 Apparently, these conflicting results studying
the Tfh B-cell interaction of belatacept require further
investigation.
6 | CONCLUSION
The importance of Tfh and Tfr cells is mainly reported in B-
cell-mediated autoimmune disease. In organ transplant recip-
ients, studies on cTfh cells and their subsets Tfh1, Tfh2 and
Tfh17 are limited. Studies measuring Tfr cells in transplanta-
tion are even more scarce. From literature it is clear that cTfh
cells play a role in DSA formation. Moreover, the role of IL-
21 and a higher percentage of cTh cells during rejection and
lower percentage cTfh in tolerant patients implies the impor-
tance of monitoring these special cells. However, the role of
Tfr cells in tempering DSA formation to prevent ABMR is
not yet elucidated. Although, avoiding de novo DSA forma-
tion will increase transplant survival and suggests the impor-
tance of studying the Tfh/Tfr ratio. Therefore, it will be
attractive to monitor the Tfh/Tfr ratio in combination with
IL-21 in the first year after transplantation as potential bio-
markers to identify patients at risk for ABMR. In addition,
targeting the molecules leading to alloantigen activation and
IL-21 secretion of Tfh cells will be a relevant approach to
prevent B cell differentiation and subsequent production of de
novo DSA resulting in a decrease in the incidence of ABMR.
Furthermore, understanding the role of donor-specific Tfh
and Tfr cells in the humoral immune response should be per-
formed including their specific proteome profile in combina-
tion with different immunosuppressive medication. This will
unravel the biological function of these cells in the organ
transplant setting, and lead to improved therapeutic strategies
with the ultimate goal of personalized immunosuppressive
medication in patients at risk for ABMR.
In summary, there is a requirement for a robust bio-
marker for identification of patients at risk for de novo DSA
formation and development of ABMR. In addition, the
knowledge of the biological mechanisms underlying ABMR
could be a step forward to improve therapeutic regimens and
to develop novel therapeutic strategies to both prevent and
treat ABMR resulting in a higher allograft survival.
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